These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10938510)

  • 21. Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C.
    Guilera M; Forns X; Torras X; Enríquez J; Coll S; Solà R; Morillas R; Planas R; Ampurdanès S; Soler M; Costa J; Sáiz JC; Sánchez-Tapias JM; Rodés J
    J Hepatol; 2000 Jul; 33(1):135-41. PubMed ID: 10905597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison.
    Tong MJ; Blatt LM; McHutchison JG; Co RL; Conrad A
    Hepatology; 1997 Dec; 26(6):1640-5. PubMed ID: 9398010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy.
    Izopet J; Payen JL; Alric L; Sandres K; Charlet JP; Vinel JP; Duffaut M; Pascal JP; Puel J
    J Med Virol; 1998 Feb; 54(2):86-91. PubMed ID: 9496364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study.
    Flichman D; Colombatto P; Randone A; Baldi M; Bellati G; Negro F; Oliveri F; Colucci G; Verme G; Bonino F; Brunetto MR
    Clin Diagn Virol; 1997 May; 8(1):63-70. PubMed ID: 9248659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.
    Orito E; Mizokami M; Suzuki K; Ohba K; Ohno T; Mori M; Hayashi K; Kato K; Iino S; Lau JY
    J Med Virol; 1995 Jun; 46(2):109-15. PubMed ID: 7636496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon retreatment in chronic hepatitis C: which patients to choose, and what schedule to use.
    Picciotto A; Campo N; Brizzolara R; Sinelli N; Torre F; Cipriani AG; Ponassi I; Varagona G; Grasso A; De Leo P; De Conca V; Mesiti S; Marenco G; Menardo G; Dodero M; Celle G
    Eur J Gastroenterol Hepatol; 1999 Jun; 11(6):649-53. PubMed ID: 10418937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.
    Fong TL; Han SH; Tsai NC; Morgan TR; Mizokami M; Qian D; Phan C; Goad K; Redeker AG
    J Hepatol; 1998 Mar; 28(3):369-74. PubMed ID: 9551672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained response to interferon-alpha2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C. The Donor Surveillance Study Group.
    Prati D; Zanella A; Zanuso F; Vianello L; Della Torre E; Mozzi F; Carriero PL; Zahm F; Donato MF; Colombo M; Sirchia G
    J Viral Hepat; 2000 Sep; 7(5):352-60. PubMed ID: 10971823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
    Giannini EG; Basso M; Savarino V; Picciotto A
    Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study.
    Tassopoulos NC; Vafiadis I; Tsantoulas D; Syrokosta J; Hatzis G; Delladetsima JK; Demonakou M; Sypsa V; Hatzakis AE
    J Interferon Cytokine Res; 2002 Mar; 22(3):365-9. PubMed ID: 12034044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term biochemical and virological response to natural interferon-alpha in patients with chronic hepatitis C.
    Hagiwara H; Hayashi N; Kasahara A; Oshita M; Katayama K; Naito M; Masuzawa M; Yoshihara H; Shimizu Y; Fusamoto H; Kamada T
    Dig Dis Sci; 1996 May; 41(5):1001-7. PubMed ID: 8625742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
    Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
    Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
    Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.
    Inoue K; Sekiyama K; Yamada M; Watanabe T; Yasuda H; Yoshiba M
    J Gastroenterol; 2003; 38(6):567-72. PubMed ID: 12825133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.